Frequently Asked Questions

FAQs

  • Ask a question?

Didn’t find what you are looking for? Fill the form and we will get back as soon as possible.

1. Hydroxychloroquine for prevention of COVID-19

Swahili Version

Mtafiti mkuu wa hapa nchini ni Dkt Anthony Etyang: barua pepe Aetyang@kemri-wellcome.org Simu +254 722 417507

Utafiti huu umeidhinishwa na mamlaka za uthibiti hapa Kenya na unatarajiwa kuanza kusajili watu hapo mwezzi wa 10, 2020. Ufuatilizi wa washiriki unatarajiwa kukamilika kufikia mwezi wa Tatu,2021 na majibu yachapishwe muda mfupi baadaye.

English Version

The study has been approved by regulatory authorities in Kenya and is expected to start recruitment in October 2020. Participant follow up is expected to be completed by March 2021 and results published shortly thereafter.

The study may show a benefit of using hydroxychloroquine which would save many lives around the world, or alternatively may show hydroxychloroquine prophylaxis is ineffective so trials can move on to evaluate other possible interventions.

2. ChAdOx1 nCOV-19 Vaccine Trial

Swahili Version

Tayari tuko na habari nyingi kuhusu usalama na ubora wa utendajikazi wa chanjo hii, hatuwezi kujua ni lini tutakapoweza kuamua ikiwa chanjo inakinga ugonjwa. Hii itategemea janga, pale wagonjwa wanapopungua, ni vigumu kujua ikiwa chanjo inakinga ugonjwa.
Majaribio haya yamefadhiliwa na Wellcome Trust na chuo kikuu cha Oxford.

English Version

We already have a lot of information on safety and how well the vaccine works, it’s unclear when we will determine if the vaccine prevents disease. This will depend on the pandemic, as cases fall it’s harder to demonstrate that the vaccine prevents disease.
The trial is being funded by the Wellcome Trust and Oxford University as the sponsor.

FAQs for ChAdOx1 nCoV-19 Vaccine Trial (Questions brought about by the on-going vaccine roll out by MoH)

Swahili Version

Serikali, kupitia wizara ya afya inapeana chanjo ya AstraZeneca/Oxford (Covishield) inayoitwa chanjo ya ChAdOx1 nCoV-19. Hii ndiyo chanjo ambayo KEMRI Kilifi inaifanyia majaribio.

Upeanaji wa chanjo ya COVID-19 wa serikali unalenga makundi ya walengwa kwa mtindo wa awamu. Takwimu zitokanazo na majaribio yanayoendelea zitaendelea kujulisha utekelezaji wa muda mrefu wa chanjo ya COVID-19 hapa Kenya katika awamu zinazofuata.

English Version

The vaccine has been approved in very many countries across the world and is being rolled out to the general population including those with underlying conditions. As of 7th March 2021, 22,377,255 doses of at least 1 COVID-19 vaccine had been given to UK residents. This would primarily be the Oxford/Astra Zeneca Vaccine and includes individuals with underlying conditions. No safety concerns have been identified in these groups since the vaccine has been rolled out across several countries. In phase 2/3 trials in the UK, South Africa and Brazil 11,636 individuals were recruited including older adults and individuals with a range of underlying conditions (cardiovascular, respiratory and diabetes) and there were no safety concerns identified in these groups.

The role of monitoring vaccine serious side effects sits within Ministry of Health, through the National Vaccine Immunization Programme (NVIP), which will monitor all serious side effects following immunization. The Pharmacy and Poisons Board of Kenya is also tracking any serious side effects following immunization through reports generated at sub-county and county level.

Do you have COVID-19 Symptoms?

Visit the nearest health center to get tested.